Regulatory Clearance for Eve®, Leo’s patient positioning system

We are delighted to share the news that Leo Cancer Care has gained regulatory 510(k) clearance for Eve®, its revolutionary upright patient positioning system for delivering radiotherapy treatment to patients.

Leo’s patient positioning system Eve® enables cancer patients to receive radiation treatment seated in an upright position. Research has shown that the approach is a more natural position for patients, with evidence suggesting that this will contribute to less internal organ movement leading to more efficient delivery of radiotherapy. Studies have also shown that patients prefer to be in the upright position, rather than lying down.

CEO Stephen Towe welcomes the landmark ruling, “Leo Cancer Care has always promised a lot; a new paradigm for radiation therapy with huge potential benefits for patients across the globe.“ “This regulatory clearance marks a turning point for the company and our ability to deliver on those promises. This will see clinical adoption of the upright treatment approach giving patients the choice they have been waiting for.“

The FDA regulatory clearance for Leo Cancer Care’s upright technology is a truly significant step in the company’s evolution. With one device cleared, Leo has a comprehensive development pipeline to deliver further solutions within the upright technology paradigm- watch this space!